Monte Rosa reports positive Phase 1 GFORCE-1 results for MRT-8102 in elevated CVD-risk subjects

Bitget2026/10/01 11:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Monte Rosa Therapeutics reported positive Phase 1 GFORCE-1 results for MRT-8102 in obese subjects with elevated cardiovascular risk.
Findings were presented now, with a conference call and webcast scheduled for today.
Treatment lowered multiple inflammatory and clotting-related disease drivers toward levels seen in healthy volunteers, supporting its proposed cardiovascular rationale.
Safety profile looked comparable to placebo over dosing and follow-up, with no serious adverse events reported.
Phase 2 studies are planned in coronary artery disease in H1 2027, with additional mid-stage trials in gout and hidradenitis suppurativa.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010700PRIMZONEFULLFEED9837501) on October 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Monte Rosa reports positive Phase 1 GFORCE-1 results for MRT-8102 in elevated CVD-risk subjects

You may also like

Crypto prices